[go: up one dir, main page]

WO2003084469A3 - Tissue-specific endothelial membrane proteins - Google Patents

Tissue-specific endothelial membrane proteins Download PDF

Info

Publication number
WO2003084469A3
WO2003084469A3 PCT/US2003/010195 US0310195W WO03084469A3 WO 2003084469 A3 WO2003084469 A3 WO 2003084469A3 US 0310195 W US0310195 W US 0310195W WO 03084469 A3 WO03084469 A3 WO 03084469A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
specific
ligand
therapeutic moiety
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/010195
Other languages
French (fr)
Other versions
WO2003084469A2 (en
Inventor
Paul W Roben
Anthony C Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Utah Ventures II LP
Original Assignee
Utah Ventures II LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Utah Ventures II LP filed Critical Utah Ventures II LP
Priority to CA002481334A priority Critical patent/CA2481334A1/en
Priority to GB0423854A priority patent/GB2403222A/en
Priority to AU2003222185A priority patent/AU2003222185A1/en
Publication of WO2003084469A2 publication Critical patent/WO2003084469A2/en
Priority to US10/794,899 priority patent/US20040146516A1/en
Publication of WO2003084469A3 publication Critical patent/WO2003084469A3/en
Anticipated expiration legal-status Critical
Priority to GBGB0424024.8A priority patent/GB0424024D0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods and compositions for targeting of pharmaceuticals or other therapeutics to specific tissues using tissue-specific endothelial membrane proteins are provided. The compositions comprise a therapeutic complex composed of a ligand, a linker, and a therapeutic moiety, where the therapeutic moiety can enter the cell. The ligand can be an antibody or other molecule that binds to a tissue-specific protein on the endothelial membrane of a specific tissue. The ligand does not activate a receptor, but may activate endocytosis. The therapeutic moiety could be a drug, gene, antisense oligonucleotide, contrast agent, protein, toxin, or any type of molecule that acts on the specific tissue. The linker is preferably cleaved upon going to the interior of the cell. Alternatively, the linker may simply be the bond between the ligand and the therapeutic moiety. Alternatively, a lipophilic prodrug may be cleaved and may enter the cell due to its lipophilic properties.
PCT/US2003/010195 1999-06-17 2003-03-31 Tissue-specific endothelial membrane proteins Ceased WO2003084469A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002481334A CA2481334A1 (en) 2002-04-01 2003-03-31 Tissue-specific endothelial membrane proteins
GB0423854A GB2403222A (en) 2002-04-01 2003-03-31 Tissue-specific endothelial membrane proteins
AU2003222185A AU2003222185A1 (en) 2002-04-01 2003-03-31 Tissue-specific endothelial membrane proteins
US10/794,899 US20040146516A1 (en) 1999-06-17 2004-03-05 Lumen-exposed molecules and methods for targeted delivery
GBGB0424024.8A GB0424024D0 (en) 2002-04-01 2004-10-29 Tissue-specific endothelial membrane proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36945202P 2002-04-01 2002-04-01
US60/369,452 2002-04-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/794,899 Continuation-In-Part US20040146516A1 (en) 1999-06-17 2004-03-05 Lumen-exposed molecules and methods for targeted delivery

Publications (2)

Publication Number Publication Date
WO2003084469A2 WO2003084469A2 (en) 2003-10-16
WO2003084469A3 true WO2003084469A3 (en) 2004-06-10

Family

ID=28791952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010195 Ceased WO2003084469A2 (en) 1999-06-17 2003-03-31 Tissue-specific endothelial membrane proteins

Country Status (4)

Country Link
AU (1) AU2003222185A1 (en)
CA (1) CA2481334A1 (en)
GB (2) GB2403222A (en)
WO (1) WO2003084469A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512176B2 (en) 2005-03-31 2016-12-06 Centre National De La Recherche Scientifique Age inhibitors
US10509037B2 (en) 2004-02-12 2019-12-17 Eisai, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239910A1 (en) 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
AU2007301981A1 (en) 2006-09-25 2008-04-03 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
FI20075278A0 (en) 2007-04-20 2007-04-20 Biotie Therapies Corp Novel completely human anti-VAP-1 monoclonal antibodies
PL2197903T3 (en) 2007-09-04 2015-03-31 Us Gov Health & Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
KR20160060660A (en) 2013-10-01 2016-05-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Compounds for affinity chromatography and for extending the half-life of a therapeutic agent
CN112535726B (en) * 2019-09-05 2023-09-12 南京安吉生物科技有限公司 A kind of tumor marker AQUAPORIN 2 protein and its application
EP4601696A1 (en) * 2022-10-14 2025-08-20 Flagship Pioneering Innovations VII, LLC Compositions and methods for targeted delivery of therapeutic agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002178A1 (en) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting of liposomes to the blood-brain barrier
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US20030082176A1 (en) * 2001-04-30 2003-05-01 Symbiontics, Inc. Subcellular targeting of therapeutic proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
WO1994002178A1 (en) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting of liposomes to the blood-brain barrier
US20030082176A1 (en) * 2001-04-30 2003-05-01 Symbiontics, Inc. Subcellular targeting of therapeutic proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FISHER R.S. ET AL.: "Potential new methods for antiepileptic drug delivery", CNS DRUGS, vol. 16, no. 9, 2002, pages 579 - 593, XP002972018 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10509037B2 (en) 2004-02-12 2019-12-17 Eisai, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
US9512176B2 (en) 2005-03-31 2016-12-06 Centre National De La Recherche Scientifique Age inhibitors

Also Published As

Publication number Publication date
WO2003084469A2 (en) 2003-10-16
CA2481334A1 (en) 2003-10-16
GB0424024D0 (en) 2004-12-01
GB0423854D0 (en) 2004-12-01
AU2003222185A1 (en) 2003-10-20
GB2403222A (en) 2004-12-29

Similar Documents

Publication Publication Date Title
WO2002100336A3 (en) Tissue-specific endothelial membrane proteins
Reguera et al. Multicomponent reactions in ligation and bioconjugation chemistry
Wu et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms
Gabrielson et al. Efficient polyethylenimine-mediated gene delivery proceeds via a caveolar pathway in HeLa cells
Krall et al. Small targeted cytotoxics: current state and promises from DNA‐encoded chemical libraries
Paranjpe et al. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation
WO2005082023A3 (en) Heterocyclic self-immolative linkers and conjugates
AU2002337954B2 (en) Integrin targeting compounds
WO2002036161A3 (en) Novel targeted compositions for diagnostic and therapeutic use
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
WO2007018431A3 (en) Triazole-containing releasable linkers and conjugates comprising the same
WO2008073162A3 (en) Lysine acetylation sites
WO2002087510A3 (en) Subcellular targeting of therapeutic proteins
WO2008079973A3 (en) Egfr binding peptides and uses thereof
WO2005097202A3 (en) Use of serum albumin binding peptides conjugates for the preparation of a medicament
WO2005054279A8 (en) Delivery peptides, their constructs with active agents and use
WO2005035550A3 (en) Dual phase-pna conjugates for the delivery of pna through the blood brain barrier
WO2001066753A3 (en) Human genes and gene expression products
WO2002014500A3 (en) Human genes and gene expression products
WO2001077145A3 (en) Integrin binding peptide derivatives
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO2003084469A3 (en) Tissue-specific endothelial membrane proteins
WO2005012489A3 (en) Targeting endothelium for tissue-specific delivery of agents
WO1999064594A3 (en) Genes and gene expression products that are differentially regulated in prostate cancer
WO2002087497A3 (en) Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 0423854

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20030331

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2481334

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003222185

Country of ref document: AU

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP